Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-α levels in the mouse

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 1, 1999, Pages 199-203

  Gozzi, Peter ^a,b   Påhlman, Ingrid ^a   Palmér, Lena ^a   Grönberg, Alvar ^a   Persson, Stefan ^a  

^a Pharmacia and Upjohn AB ^*  (Sweden)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; LIPOPOLYSACCHARIDE; SUSALIMOD; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; BLOOD SAMPLING; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DOSE RESPONSE; DRUG POTENCY; FEMALE; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BENZOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ESCHERICHIA COLI; FEMALE; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344329899     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bondeson J (1997) The mechanism of action of disease-modifying antirheumatic drugs: A review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol 29:127-150.
2. Boxtel CJ, Holford NHG and Danhof M (1992) The In Vivo Study of Drug Action, Elsevier Publishing Co., Amsterdam.
3. Breimer DD and Danhof M (1997) Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. Clin Pharmacokinet 32:259-267.
4. Danhof M and Mandema JW (1995) Modeling of relationships between pharmacokinetics and pharmacodynamics, in Pharmacokinetics: Regulatory-Industrial-Academic Perspectives (Welling PG and Tse FLS eds) 2nd ed., pp 139-174, Marcel Dekker, New York.
5. Danis VA, Franic GM, Rathjen DA, Laurent RM and Brooks PM (1992) Circulating cytokine levels in patients with rheumatoid arthritis: Results of a double blind trial with sulphalarine Ann Rheum Dis 51:946-950.
6. Dayneka NL, Garg V and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharmacol 21:457-478.
7. DeForge LE, Nguyen DT, Kunkel SL and Remick DG (1990) Regulation of the pathophysiology of tumor necrosis factor. J Lab Clin Med 116:429-438.
8. Gabrielsson J and Weiner D (1997) Pharmacokinetic and Pharmacodynamic Data Analysis, 2nd ed., Swedish Pharmaceutical Press, Stockholm, Sweden.
9. Giroir BP (1993) Mediators of septic chock: New approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 21:780-789.
10. Han J, Thompson P and Beutler B (1990) Dexamethasone and pentoxifylline inhibit endotoxin-induced cachetin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172:391-394.
11. Holford NHG and Sheiner LB (1981) Understanding the dose-response relationship: Clinical application of pharmacokinetic-pharmacodynamic models Clin Pharmacokinet 6:429-453.
12. Jusko WJ and Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419.
13. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680.
14. Påhlman I, Edholm M, Kankaanranta S and Odell M-L (1998) Pharmacokinetics of susalimod, a highly biliary-excreted sulphasalazine analogue, in various species. Nonpredictable human clearance by allometric scaling. Pharm Pharmacol Commun 4:493-498.
15. Remick DG, Stricter RM, Lynch III JP, Nguyen D, Eskandari M and Kunkel SL (1989) In vivo dynamics of murine tumour necrosis factor-alpha gene expression. Kinetics of dexamethasone-induced supression. Lab Invest 60:76-771.
16. Remick DG (1995) Applied molecular biology of sepsis. J Crit Care 10:198-212.
17. Shapira L, Soskolne Wa, Houri Y, Barak V, Halabi A and Stabholz A (1996) Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracykline: Correlation with inhibition of cytokine excretion. Infect Immun 64: 825-828.
18. Sheiner LB, Stanski DH, Vozeh S, Miller RD and Ham J (1979) Simultaneous modelling of pharmcokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371.
19. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch III JP, Larrick J and Kunkel SL (1988) Cellular and molecular regulation of tumor necrosis-alpha production by pentoxifylline. Biochem Biophys Res Commun 155:1230-1236.
20. Su GL, Simmons RL and Wang SC (1995) Lipopolysaccharide binding protein participation in cellular activation by LPS. Crit Rev Immunol 15:201-214.
21. Wollenberg GK, DeForge LE, Bolgos G and Remick DG (1993) Differential expression of tumour necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am J Pathol 143:1121-1130.
22. Yacobi A, Skelly JP, Shah VP and Benet LZ (1993) Integration of Pharmacokinetics and Pharmacodynamics in Rational Drug Development, Plenum Press, New York.